---
title: BioAgilytix vs ICON plc
slug_a: bioagilytix
slug_b: iconplc
site: cro
review_signal_gate: closed
canonical_path: /compare/bioagilytix/iconplc
---

# BioAgilytix vs ICON plc

Side-by-side profile data from each company listing on this directory.

## BioAgilytix

- Profile: [/companies/bioagilytix](/companies/bioagilytix)

BioAgilytix — Bioanalytical CRO specializing in pharmacokinetics, immunogenicity, biomarkers, and CMC analytics with 30+ years of experience and 1,100+ employees conducting 5M+ tests annually.

Services: 11. Modalities: 4. Indications: 0. Locations: 8. Certifications: 0. The strongest documented coverage currently appears in services (11).

### Services

- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Analytical Method Development & Validation
- ICH Stability Studies
- Virology Services

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Vaccine

### Indications

- Data not yet provided.

### Phases

- Discovery
- Preclinical (General)
- Phase I
- Phase II
- Phase III
- Phase IV

### Sourcing models

- Full-Service Outsourcing (FSO)

## ICON plc

- Profile: [/companies/iconplc](/companies/iconplc)

ICON plc — ICON is a global clinical research organization providing full-service drug development and clinical trial solutions across early phase through post-marketing, including clinical operations, bioanalytical labs, cardiac safety, medical imaging, and regulatory affairs.

Services: 29. Modalities: 6. Indications: 9. Locations: 52. Certifications: 0. The strongest documented coverage currently appears in locations (52).

### Services

- Bioanalysis
- LC-MS Bioanalysis (Small Molecule)
- Ligand-Binding Bioanalysis (Large Molecule)
- Immunogenicity Assays (ADA / NAb)
- Biomarker Assays
- Flow Cytometry Services
- Clinical Trial Services
- Phase I Clinical Trials
- Phase II Clinical Trials
- Phase III Clinical Trials
- Phase IV / Post-Marketing
- Clinical Operations
- Data Management & eClinical
- Biostatistics & Statistical Programming
- Pharmacovigilance & Drug Safety
- Medical Writing
- Central Laboratory Services
- Clinical Imaging Core Lab
- Regulatory Affairs
- US FDA Regulatory Strategy
- EU EMA Regulatory Strategy
- Japan PMDA Regulatory Strategy
- China NMPA Regulatory Strategy
- Translational Research
- Companion Diagnostics Development
- Immunology & Inflammation Services
- Oncology Specialty Services
- CNS Specialty Services
- Cardiovascular & Metabolic Specialty Services

### Modalities

- Small Molecule
- Biologics (Monoclonal Antibodies)
- Biologics (Other)
- Cell Therapy
- Gene Therapy
- Vaccine

### Indications

- Oncology
- Immunology
- Neurology
- Metabolic
- Cardiovascular
- Infectious Disease
- Rare Disease
- Ophthalmology
- Women's Health

### Phases

- Phase I
- Phase II
- Phase III
- Phase IV
- Real-World Evidence (RWE) / Registries

### Sourcing models

- Full-Service Outsourcing (FSO)
- Functional Service Provider (FSP)